Kavuru Vimal Kumar
Direktor/Vorstandsmitglied bei Cronus Pharma Specialities India Pvt Ltd.
Profil
Kavuru Vimal Kumar has worked as a Director at Cronus Pharma Specialities India Pvt Ltd.
since 2018 and at Casper Pharma Pvt Ltd.
since 2016.
Aktive Positionen von Kavuru Vimal Kumar
Unternehmen | Position | Beginn |
---|---|---|
Cronus Pharma Specialities India Pvt Ltd.
Cronus Pharma Specialities India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Cronus Pharma Specialities India Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Hyderabad, India and was founded in 2015. | Direktor/Vorstandsmitglied | 16.07.2018 |
Casper Pharma Pvt Ltd.
Casper Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Suven Pharmaceuticals Ltd., Casper Pharma Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The company is based in Hyderabad, India. The company was founded in 2016. Casper Pharma was acquired by Suven Pharmaceuticals Ltd. on June 30, 2022 for $20.75 million. | Direktor/Vorstandsmitglied | 13.01.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Cronus Pharma Specialities India Pvt Ltd.
Cronus Pharma Specialities India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Cronus Pharma Specialities India Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Hyderabad, India and was founded in 2015. | Health Technology |
Casper Pharma Pvt Ltd.
Casper Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Suven Pharmaceuticals Ltd., Casper Pharma Pvt Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical products. The company is based in Hyderabad, India. The company was founded in 2016. Casper Pharma was acquired by Suven Pharmaceuticals Ltd. on June 30, 2022 for $20.75 million. | Health Technology |